Wegovy in India 2026: Cost, Availability, and How to Get It Legally
Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injection from Novo Nordisk. It is the same molecule as Ozempic — but at a higher dose, and specifically approved for chronic weight management, not diabetes. If you've been searching for it in India, the picture is messy: imported by some patients, prescribed off-label as Ozempic by others, and frequently confused with both. This guide explains what is actually available, what it costs, and the only legal way to access it.
What Wegovy actually is
Wegovy is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness after meals, slows gastric emptying, and reduces appetite-driving hunger signals. The 2.4 mg weekly dose is what separates Wegovy from Ozempic (max 2 mg, dosed for blood sugar control). In the STEP clinical trials, Wegovy users lost an average of 14.9% of body weight over 68 weeks — outcomes previously only seen with bariatric surgery.
Wegovy is a prescription-only injection, supplied as a pre-filled pen. It is not a fat-burner, not a supplement, and not safe to import casually.
Wegovy availability in India
Novo Nordisk launched Wegovy in India in June 2025, initially through hospital pharmacies and licensed e-pharmacies in metros (Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Pune). In December 2025 they announced an Emcure Pharma partnership to expand distribution under the Poviztra brand, broadening reach into tier-2 cities. Availability has improved substantially through 2026.
Two important context updates:
- Ozempic (semaglutide 0.25 – 2 mg) has been available longer for type 2 diabetes, and has historically been prescribed off-label for weight management.
- Wegovy (semaglutide 2.4 mg) is the higher-dose, weight-management-indicated formulation.
Generic semaglutide is now available in India. The semaglutide patent expired in India on March 20, 2026, and at least 5 Indian manufacturers (including Cipla, Sun Pharma, Dr Reddy's, Lupin, and Biocon) have launched generic versions, undercutting branded Wegovy by up to 80%. This is reshaping access dramatically — your doctor will discuss whether branded or generic is appropriate for you.
If you're being offered "Wegovy from a private importer" without a prescription, that supply is almost certainly either counterfeit, mis-stored (Wegovy needs cold chain), or both — regardless of generic availability.
Wegovy price in India (current)
Wegovy was launched in June 2025 at ₹17,000 – ₹26,000 per month, then Novo Nordisk reduced the price by 37% in November 2025. Current branded Wegovy pricing in India:
| Dose | Approx. monthly cost |
|---|---|
| 0.25 mg (start) / 0.5 mg | ₹10,850 – ₹12,500 |
| 1.0 mg | ₹12,500 – ₹14,200 |
| 1.7 mg | ₹14,200 – ₹15,500 |
| 2.4 mg (maintenance) | ₹15,500 – ₹16,400 |
Generic semaglutide (post-March 2026 patent expiry) is available at ₹3,000 – ₹6,000 per month at the equivalent dose from licensed Indian manufacturers. Your doctor will discuss appropriateness based on your insurance situation, manufacturer track record, and clinical fit.
The headline drug price isn't the full cost. To do this safely, you also need:
- An initial medical consultation (₹1,000 – ₹3,000)
- Blood work (CBC, fasting glucose, HbA1c, lipid panel, TSH, kidney + liver panel — typically ₹2,500 – ₹5,000)
- Follow-up consultations every 4 – 6 weeks for dose titration and side-effect management
At Stride, our 3-Month Early Edition is ₹9,999 (regular ₹23,999). It bundles assessment, at-home blood test, doctor video consultations, monthly GLP-1 medication delivery when clinically appropriate, and continuous nutrition support — so you're not chasing pharmacies, lab partners, and clinician appointments separately.
Eligibility: who Wegovy is for
Wegovy is indicated for adults with:
- BMI ≥ 30 kg/m² (obesity), or
- BMI ≥ 27 kg/m² with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnoea, established cardiovascular disease)
It is not appropriate if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN2), severe gastrointestinal disease (e.g., gastroparesis), or are pregnant / trying to conceive. Your doctor's job is to rule these out before prescribing.
The legal path to Wegovy in India
There are exactly two compliant routes:
- In-person clinic — endocrinologist or obesity specialist, in-person consultation, prescription, then pharmacy purchase.
- Telemedicine — under the Telemedicine Practice Guidelines (2020), a registered Indian medical practitioner can prescribe Wegovy after video consultation, provided medical history, BMI, and lab results are reviewed.
Both routes require a valid prescription, authenticated pharmacy sourcing (cold-chain handling matters for biologics), and ongoing monitoring. Buying Wegovy from anywhere that doesn't ask for a prescription and labs is illegal and unsafe.
What to expect on Wegovy
Dose escalation is mandatory — you don't start at 2.4 mg. The standard schedule is:
| Week | Dose |
|---|---|
| 1 – 4 | 0.25 mg / week |
| 5 – 8 | 0.5 mg / week |
| 9 – 12 | 1.0 mg / week |
| 13 – 16 | 1.7 mg / week |
| 17+ | 2.4 mg / week (maintenance) |
This gradual ramp is what keeps side effects manageable. The most common: nausea (affects ~44%), constipation, diarrhoea, mild reflux, and reduced appetite (the desired effect). Most settle within 4 – 8 weeks. Rare but serious effects include pancreatitis and gallbladder disease — your care team monitors for these.
Expected weight loss: 5 – 8% by month 3, 10 – 12% by month 6, 14 – 17% by month 12, with diet and movement support. People who treat Wegovy as "the only thing they need" tend to underperform; people who pair it with structured nutrition and adequate protein tend to outperform.
How Stride fits
Stride is built around the recognition that Wegovy works best as one element of a continuous medical program, not as a standalone prescription. The 3-Month Early Edition includes:
- Online assessment (gender, weight, height, history, conditions, goals)
- At-home blood test, scheduled at 8 AM on a date you choose
- One-on-one video consultation with an Indian-licensed clinician
- GLP-1 medication delivery monthly, when clinically appropriate
- Personalized nutrition support and ongoing accountability
One-time payment. No auto-renewal.
Frequently asked questions
Is Wegovy legally available in India in 2026? Yes — Novo Nordisk launched Wegovy in India in June 2025, with expanded distribution via the December 2025 Emcure partnership (Poviztra brand). A prescription from a registered Indian medical practitioner is mandatory.
What is the current Wegovy price in India? After the November 2025 price cut, branded Wegovy ranges from ₹10,850 (lowest dose) to ₹16,400 (2.4 mg maintenance) per month. Generic Indian semaglutide (available since March 2026) costs ₹3,000 – ₹6,000 monthly. Bundle costs (consultation + labs + monitoring) add ₹4,000 – ₹8,000 over a full course.
Can I get a Wegovy prescription via an online consultation in India? Yes — under the Telemedicine Practice Guidelines (2020), a registered Indian doctor can prescribe Wegovy after video consultation and review of your medical history and labs.
Is Wegovy the same as Ozempic? Same molecule (semaglutide). Different dose and indication. Ozempic max 2 mg / week for type 2 diabetes; Wegovy 2.4 mg / week specifically approved for chronic weight management.
Will my insurance cover Wegovy? Most Indian retail health insurance policies do not currently cover obesity medications, though some corporate and premium policies do. Check the "weight management" or "lifestyle disease" rider on your specific policy before assuming coverage.
What are the main side effects to expect? Nausea, constipation, diarrhoea, and reduced appetite are common in the first 4 – 8 weeks. They typically settle as your body adjusts. Severe abdominal pain, persistent vomiting, or signs of an allergic reaction warrant immediate medical attention.
Ready to start?
If Wegovy is right for you — and only your doctor can determine that — Stride's 3-Month Early Edition is the most straightforward way to access it safely in India.
Doctor-led, continuously monitored.
3-Month Early Edition: ₹9,999 (regular ₹23,999). One-time payment, no auto-renewal.
Check Your Eligibility →